ATXS — Astria Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $494.22m
- $343.01m
- 36
- 19
- 81
- 42
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 36.2 | 44.9 | 126 | 226 | 247 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 39 | 46.3 | 127 | 228 | 251 |
Net Property, Plant And Equipment | 2.35 | 0.966 | 0.394 | 0.948 | 0.363 |
Other Long Term Assets | |||||
Total Assets | 41.8 | 47.5 | 128 | 231 | 255 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 5.03 | 6.39 | 5.2 | 9.06 | 11.6 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.06 | 6.79 | 5.2 | 9.42 | 11.6 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 35.7 | 40.7 | 122 | 221 | 243 |
Total Liabilities & Shareholders' Equity | 41.8 | 47.5 | 128 | 231 | 255 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |